For the quarter ending 2026-03-31, LXRX had $3,763K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,043 | -15,530 | -12,768 | -22,043 |
| Depreciation and amortization | 110 | 118 | 151 | 352 |
| Stock-based compensation | 3,078 | 2,835 | 3,444 | 6,238 |
| Amortization of debt-related costs | 681 | 495 | 402 | 803 |
| Accretion of marketable securities purchased at a discount | 562 | 440 | 732 | 2,540 |
| Other non-cash adjustments | 581 | 163 | 18 | 1,561 |
| (increase) decrease in accounts receivable, net | 9,395 | 50 | 151 | -1,290 |
| Decrease in inventories | -5 | 123 | -10 | -63 |
| (increase) decrease in prepaid expenses and other current assets | 319 | -1,084 | 358 | -806 |
| Decrease in other long-term assets | -195 | -190 | -191 | -376 |
| Decrease in accounts payable and other liabilities | -6,899 | -5,649 | -14,004 | -10,569 |
| Net cash used in operating activities | -14,730 | -17,233 | -23,833 | -26,785 |
| Purchases of property and equipment | - | 0 | 0 | 0 |
| Purchases of investments | 105,960 | 22,170 | 26,725 | 90,943 |
| Maturities of investments | 35,697 | 27,000 | 78,850 | 147,008 |
| Net cash (used in) provided by investing activities | -70,263 | 4,830 | 52,125 | 56,065 |
| Proceeds from debt borrowings, net of fees | - | 0 | - | - |
| Proceeds from issuance of common stock, net of fees | 69,986 | 0 | - | - |
| Other debt financing fees | - | 0 | 0 | 0 |
| Proceeds from issuance of preferred stock, net of fees | 26,548 | 0 | 0 | 0 |
| Proceeds from issuance of common stock for equity incentive plans | 65 | 73 | 0 | 0 |
| Payments for tax withholding on share-based compensation vesting | 2,843 | 0 | 0 | 572 |
| Repayment of debt borrowings | 5,000 | 3,000 | 0 | 45,000 |
| Net cash provided by (used in) financing activities | 88,756 | -2,927 | 0 | -45,572 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 3,763 | -15,330 | 28,292 | -16,292 |
| Cash, cash equivalents, and restricted cash at beginning of period | 63,326 | 78,656 | 66,656 | - |
| Cash, cash equivalents, and restricted cash at end of period | 67,089 | 63,326 | 78,656 | - |
LEXICON PHARMACEUTICALS, INC. (LXRX)
LEXICON PHARMACEUTICALS, INC. (LXRX)